In theory, other BRAF and MEK inhibitor combinations evaluated in melanoma [38,39] and in ongoing phase 2 clinical trials in BRAF-mutated NSCLC, such as encorafenib plus binimetinib in advanced-stage (NCT03915951) (Supplementary Table S2), or vemurafenib plus cobimetinib in the neoadjuvant and adjuvant setting (NCT04302025), may also be combined with other third-generation EGFR TKIs (e.g., lazertinib, almonertinib, alflutinib) or the fourth generation EGFR TKI BLU-945. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.